Positive Phase III data with Novo Nordisk's hemophilia A follow-on
This article was originally published in Scrip
Executive Summary
Novo Nordisk has reported positive pivotal data from the first Phase III trial of its follow-on product to NovoEight (turoctocog alfa), for hemophilia A patients.